Pregled bibliografske jedinice broj: 1106588
Adropin – Potential Link in Cardiovascular Protection for Obese Male Type 2 Diabetes Mellitus Patients Treated with Liraglutide
Adropin – Potential Link in Cardiovascular Protection for Obese Male Type 2 Diabetes Mellitus Patients Treated with Liraglutide // Acta clinica Croatica, 59 (2020), 2; 243695, 7 doi:10.20471/acc.2020.59.02.19 (domaća recenzija, članak, znanstveni)
CROSBI ID: 1106588 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Adropin – Potential Link in Cardiovascular
Protection for Obese Male Type 2 Diabetes
Mellitus Patients Treated with Liraglutide
Autori
Tičinović Kurir, Tina ; Miličević, Tanja ; Novak, Anela ; Vilović, Marino ; Božić Joško
Izvornik
Acta clinica Croatica (0353-9466) 59
(2020), 2;
243695, 7
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Diabetes mellitus type 2 ; Insulin resistance ; Obesity ; Adropin ; Liraglutide ; Endothelial cell dysfunction
Sažetak
The aim of this study was to determine plasma adropin concentration and parameters of insulin resistance in obese male type 2 diabetes mellitus (T2DM) patients before and after 3- month liraglutide treatment. In this interventional study, we enrolled 15 obese male T2DM patients with body mass index (BMI) >35 kg/m2, uncontrolled disease and HbA1c >7.5%, having previously taken taking two oral antidiabetic drugs. We modified their therapy to metformin and liraglutide for the next three months. After three months of liraglutide treatment, we observed significant decrease in body weight (from 111.5±18.7 kg to 109.2±17.5 kg, p=0.016) and BMI (from 40.9±7.3 to 40.1±7.0 kg/m2, p=0.021). Plasma adropin concentration increased significantly (p=0.003) compared with baseline. Fasting plasma insulin level decreased from 17.79±6.53 to 13.38±3.51 mU/L (p=0.002), fasting plasma glucose level decreased from 8.66±3.07 to 7.41±2.21 mmol/L (p=0.004) and HbA1c decreased from 7.98±0.70% to 7.26±0.36% (p=0.003). Insulin resistance presented as HOMA-IR decreased significantly from 7.30±5.19 to 4.52±2.61 (p=0.002). Systolic blood pressure, lipid status, liver and kidney function improved, but not reaching statistical significance. Treating obese male T2DM patients with liraglutide resulted in a significantly higher plasma adropin concentration, significant weight loss and improved parameters of insulin resistance, i.e. decreased fasting plasma insulin, plasma glucose levels and HOMA- IR.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Profili:
Tanja Miličević
(autor)
Marino Vilović
(autor)
Joško Božić
(autor)
Anela Novak
(autor)
Tina Tičinović Kurir
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE